Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.98 Billion KRW | -137.73% |
| 2022 | 5.27 Billion KRW | 1413.89% |
| 2021 | -401.29 Million KRW | -106.64% |
| 2020 | 6.04 Billion KRW | 552.46% |
| 2019 | 925.93 Million KRW | -71.83% |
| 2018 | 3.28 Billion KRW | 28.19% |
| 2017 | 2.56 Billion KRW | -35.4% |
| 2016 | 3.96 Billion KRW | 89.2% |
| 2015 | 2.09 Billion KRW | 247.43% |
| 2014 | -1.42 Billion KRW | -235.91% |
| 2013 | 1.04 Billion KRW | 107.12% |
| 2012 | -14.7 Billion KRW | -547.25% |
| 2011 | 3.28 Billion KRW | -58.96% |
| 2010 | 8.01 Billion KRW | -8.38% |
| 2009 | 8.74 Billion KRW | -36.95% |
| 2008 | 13.87 Billion KRW | 9.38% |
| 2007 | 12.68 Billion KRW | -4.73% |
| 2006 | 13.31 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.39 Billion KRW | 339.94% |
| 2024 Q2 | 683.85 Million KRW | -79.87% |
| 2023 Q1 | 1.27 Billion KRW | 304.36% |
| 2023 Q4 | -1.41 Billion KRW | 56.74% |
| 2023 FY | -1.98 Billion KRW | -137.73% |
| 2023 Q3 | -3.27 Billion KRW | -329.02% |
| 2023 Q2 | 1.42 Billion KRW | 12.5% |
| 2022 FY | 5.27 Billion KRW | 1413.89% |
| 2022 Q1 | 3.09 Billion KRW | 180.01% |
| 2022 Q4 | -621.47 Million KRW | -140.58% |
| 2022 Q2 | 2.05 Billion KRW | -33.52% |
| 2022 Q3 | 1.53 Billion KRW | -25.5% |
| 2021 Q1 | 1.16 Billion KRW | 146.64% |
| 2021 Q2 | 225.51 Million KRW | -80.72% |
| 2021 Q3 | 794.07 Million KRW | 252.12% |
| 2021 Q4 | -3.86 Billion KRW | -586.73% |
| 2021 FY | -401.29 Million KRW | -106.64% |
| 2020 Q3 | 1.24 Billion KRW | -0.59% |
| 2020 Q2 | 1.25 Billion KRW | -79.52% |
| 2020 FY | 6.04 Billion KRW | 552.46% |
| 2020 Q1 | 6.11 Billion KRW | 1358.11% |
| 2020 Q4 | -2.5 Billion KRW | -301.23% |
| 2019 Q3 | 1.17 Billion KRW | -17.55% |
| 2019 FY | 925.93 Million KRW | -71.83% |
| 2019 Q1 | 2.55 Billion KRW | 349.89% |
| 2019 Q2 | 1.42 Billion KRW | -44.29% |
| 2019 Q4 | 419.65 Million KRW | -64.24% |
| 2018 FY | 3.28 Billion KRW | 28.19% |
| 2018 Q4 | 567.79 Million KRW | -62.25% |
| 2018 Q3 | 1.5 Billion KRW | 178.31% |
| 2018 Q2 | 540.45 Million KRW | -19.88% |
| 2018 Q1 | 674.58 Million KRW | 280.14% |
| 2017 Q4 | -374.48 Million KRW | -146.79% |
| 2017 Q1 | 1.17 Billion KRW | 14.2% |
| 2017 FY | 2.56 Billion KRW | -35.4% |
| 2017 Q2 | 958.82 Million KRW | -18.71% |
| 2017 Q3 | 800.37 Million KRW | -16.53% |
| 2016 Q4 | 1.03 Billion KRW | -22.4% |
| 2016 Q1 | 1.31 Billion KRW | 865.41% |
| 2016 Q2 | 288.07 Million KRW | -78.14% |
| 2016 Q3 | 1.33 Billion KRW | 361.97% |
| 2016 FY | 3.96 Billion KRW | 89.2% |
| 2015 Q3 | -466.19 Million KRW | -135.36% |
| 2015 Q4 | 136.47 Million KRW | 129.28% |
| 2015 FY | 2.09 Billion KRW | 247.43% |
| 2015 Q1 | 1.1 Billion KRW | 153.63% |
| 2015 Q2 | 1.31 Billion KRW | 18.85% |
| 2014 Q1 | -655.1 Million KRW | -156.35% |
| 2014 Q4 | -2.06 Billion KRW | -263.27% |
| 2014 Q3 | 1.26 Billion KRW | 3663.04% |
| 2014 Q2 | 33.66 Million KRW | 105.14% |
| 2014 FY | -1.42 Billion KRW | -235.91% |
| 2013 Q1 | 368.36 Million KRW | 105.9% |
| 2013 FY | 1.04 Billion KRW | 107.12% |
| 2013 Q3 | -1.07 Billion KRW | -282.08% |
| 2013 Q4 | 1.16 Billion KRW | 208.28% |
| 2013 Q2 | 589.72 Million KRW | 60.09% |
| 2012 Q4 | -6.24 Billion KRW | -653.8% |
| 2012 FY | -14.7 Billion KRW | -547.25% |
| 2012 Q2 | -4.98 Billion KRW | -95.5% |
| 2012 Q3 | -828.82 Million KRW | 83.37% |
| 2012 Q1 | -2.54 Billion KRW | 0.0% |
| 2011 Q3 | 890.49 Million KRW | -6.24% |
| 2011 Q1 | 4.01 Billion KRW | 227.48% |
| 2011 Q2 | 949.76 Million KRW | -76.34% |
| 2011 FY | 3.28 Billion KRW | -58.96% |
| 2010 Q4 | 1.22 Billion KRW | -3.88% |
| 2010 FY | 8.01 Billion KRW | -8.38% |
| 2010 Q1 | 998.09 Million KRW | -71.95% |
| 2010 Q2 | 1.49 Billion KRW | 50.22% |
| 2010 Q3 | 1.27 Billion KRW | -14.95% |
| 2009 Q2 | 1.54 Billion KRW | -25.21% |
| 2009 Q3 | 2.62 Billion KRW | 69.83% |
| 2009 Q4 | 3.55 Billion KRW | 35.52% |
| 2009 FY | 8.74 Billion KRW | -36.95% |
| 2009 Q1 | 2.06 Billion KRW | -56.96% |
| 2008 Q3 | 3.54 Billion KRW | 4.11% |
| 2008 FY | 13.87 Billion KRW | 9.38% |
| 2008 Q2 | 3.4 Billion KRW | 25.61% |
| 2008 Q4 | 4.8 Billion KRW | 35.62% |
| 2008 Q1 | 2.7 Billion KRW | -4.88% |
| 2007 Q3 | 3.68 Billion KRW | 7.08% |
| 2007 FY | 12.68 Billion KRW | -4.73% |
| 2007 Q2 | 3.44 Billion KRW | 0.0% |
| 2007 Q4 | 2.84 Billion KRW | -22.8% |
| 2006 FY | 13.31 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 645.663% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 102.587% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 97.5% |
| HANDOK Inc. | 12.57 Billion KRW | 115.813% |
| Yuhan Corporation | 74.56 Billion KRW | 102.668% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 117.794% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 88.975% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 100.885% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 165.088% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 113.861% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 433.523% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 306.393% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 107.359% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 645.663% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 74.354% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 149.314% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 97.156% |
| JW Holdings Corporation | 143.66 Billion KRW | 101.385% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 96.276% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 100.807% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 101.983% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 95.803% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 128.716% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 130.739% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 122.782% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 645.663% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 104.079% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 101.491% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 101.983% |
| Yuhan Corporation | 74.56 Billion KRW | 102.668% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 109.508% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 163.808% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 104.626% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 101.983% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 109.711% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 103.62% |
| CKD Bio Corp. | -20.15 Billion KRW | 90.13% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 106.171% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 107.862% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 106.116% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 95.803% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 106.001% |
| Boryung Corporation | 68.26 Billion KRW | 102.914% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 94.695% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 113.861% |
| JW Lifescience Corporation | 32.09 Billion KRW | 106.198% |